Capstone Therapeutics
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
8
1 to 10 range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 4 verified contacts at Capstone Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
- JH
Jock Holliman
Executive Chairman and Principal Executive Officer · Other
EmailPhone - BD
Barb Dunford
Executive Assistant · General Business & Management
EmailPhone
Showing 2 of 4 verified contacts
Top roles at Capstone Therapeutics
4 distinct titles indexed · top 4 shown.
- 1cfo
- 1director, regulatory affairs
- 1executive assistant
- 1executive chairman and principal executive officer
Sign up to unlock all 4 contacts at Capstone Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Capstone Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.